Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
One example: "Although the story didn't cite the cost of appendectomy emergency or urgent surgery and we wish it had, we nonetheless will give it a satisfactory score because it at least cited what the editorial writer wrote, ""A secondary benefit is the savings to the hospital generated by minimizing staff and anesthesiologist presence late in the evening and during the wee hours of the morning."" As with our harms score above, although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Despite running less than 300 words, this story did an adequate job in explaining the quality of the evidence, including pointing out limitations. No disease-mongering here. The story meets the bare minimum requirement for this criterion in that it at least cited what an editorial stated. The focus of the story was on a study comparing emergency appendectomy with surgery done up to 12 hours later or beyond. This is the whole focus of the story and one we applaud when it begins: ""Appendectomy is the most common emergency surgery in the world, but it doesn't have to be."" There were no claims made about the novelty of this research, and we may have wished for a bit more context on this. Nonetheless, the potential for guiding future care decisions was made clear. Not applicable. Given that the story only pulled excerpts from the journal article and the accompanying editorial, and didn't include any fresh quotes from interviews, we can't be sure of the extent to which it may have been influenced by a news release."
Solution is here: Some appendicitis cases may not require 'emergency' surgery
Explanation: The paragraph mentions that "Appendectomy is the most common emergency surgery in the world, but it doesn't have to be." which is considered evidence for the output. Thus, the output is a valid claim.

Now, solve this: The compound, from Danish biotech firm Santaris Pharma, works by blocking or "silencing" microRNAs tiny strands of RNA, or ribonucleic acid, that help turn genes into proteins. The ground-breaking study is the first demonstration of microRNA silencing in primates and an early endorsement of the technique. Phase I safety trials are now planned in humans. Unlike other drugs in the hotly pursued RNA interference field, the new designer molecule, known as Locked Nucleic Acid (LNA), can be given as a simple injection rather than having to be delivered direct to affected tissue. "We think LNA is a one-stop shop for silencing," Santaris Chief Executive Keith McCullagh told reporters. Scientists from Santaris and the University of Copenhagen lowered total cholesterol in African green monkeys by up to 30 percent, without ill effects, by targeting a microRNA linked to genes in the liver that are involved in cholesterol metabolism. The results were published in the journal Nature, along with other test-tube research showing that LNA effectively blocks the production of hepatitis C virus in human liver cells. Santaris intends to test its first LNA compounds in humans by the middle of this year but it will take at least five years before any medicine is ready for submission for approval. While the cholesterol effect is interesting, McCullagh said the most promising opportunity actually lay in pursuing LNA as a treatment for hepatitis C, a poorly treated viral disease that can cause serious liver damage. Further ahead, LNA could also have a role to play in other infectious diseases, as well as cancer and autoimmune disorders, since many disease-associated genes are regulated by microRNAs. "There are great prospects for future drug development both for liver diseases and other disease types, and Europe has the potential to match the USA in this area," said Mike Gait at the MRC Laboratory of Molecular Biology in Cambridge. Up until now, U.S. firms such as Alnylam Pharmaceuticals Inc and Sirna Therapeutics which was bought by Merck & Co Inc for $1.1 billion in October 2006 have led the field in RNA interference. Santaris last year signed a pact that could earn it more than $700 million with GlaxoSmithKline Plc, giving Europe's biggest drugmaker the right to develop certain products as antiviral medicines. That alliance did not include the new technology but McCullagh said Santaris could potentially extend the Glaxo deal. For a story on Santaris Pharma's possible IPO, please click on
Solution:
New kind of gene "silencing" drug works in monkeys.